2018
DOI: 10.3389/fphar.2018.00440
|View full text |Cite
|
Sign up to set email alerts
|

Targeting Renin–Angiotensin System Against Alzheimer’s Disease

Abstract: Renin Angiotensin System (RAS) is a hormonal system that regulates blood pressure and fluid balance through a coordinated action of renal, cardiovascular, and central nervous systems. In addition to its hemodynamic regulatory role, RAS involves in many brain activities, including memory acquisition and consolidation. This review has summarized the involvement of RAS in the pathology of Alzheimer’s disease (AD), and the outcomes of treatment with RAS inhibitors. We have discussed the effect of brain RAS in the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
73
1
1

Year Published

2019
2019
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 89 publications
(79 citation statements)
references
References 178 publications
(197 reference statements)
4
73
1
1
Order By: Relevance
“…DRIs directly inhibit generation of Ang I from angiotensinogen, acting upstream of both ARBs and ACEIs (Riccioni, 2013). RAS inhibitors can reduce Aβ deposition and its consequences, and also suppress inflammation, oxidative stress, vascular damage/ischemia, and increase acetylcholine release and glutamate uptake (Gebre et al, 2018;Lebouvier et al, 2020). Especially, ARBs can prevent impairment of the BBB and reduce infiltration of inflammatory mediators observed in many neurodegenerative disease such as AD (Gebre et al, 2018).…”
Section: Renin-angiotensin System-acting Drugsmentioning
confidence: 99%
“…DRIs directly inhibit generation of Ang I from angiotensinogen, acting upstream of both ARBs and ACEIs (Riccioni, 2013). RAS inhibitors can reduce Aβ deposition and its consequences, and also suppress inflammation, oxidative stress, vascular damage/ischemia, and increase acetylcholine release and glutamate uptake (Gebre et al, 2018;Lebouvier et al, 2020). Especially, ARBs can prevent impairment of the BBB and reduce infiltration of inflammatory mediators observed in many neurodegenerative disease such as AD (Gebre et al, 2018).…”
Section: Renin-angiotensin System-acting Drugsmentioning
confidence: 99%
“…Genome‐wide association studies identify an ACE allele as a risk factor in SLE, with the risk allele leading to increased serum ACE levels. In a randomized trial and several observational studies , ACE inhibition slowed cognitive decline in AD. These data, together with the findings from murine studies, support the potential use of ACE inhibitors as novel neuroprotective therapeutics for CD in SLE.…”
Section: Introductionmentioning
confidence: 99%
“…For the CNS, the blood–brain barrier ensures that the RAS located here is separated from the peripheral RAS and all the necessary substrates, enzymes, receptors and ligands are present in the CNS, along with the required control processes of stimulation or inhibition. The location of the RAS in the CNS has generated a new range of physiological and/or pharmacological target areas, including anxiety, learning, memory, physiological responses to stress and ischaemic stroke, apart from the centrally regulated effects on the peripheral cardiovascular system (Gebre, Altaye, Atey, Tuem, & Berhe, 2018; Gironacci, Vicario, Cerezo, & Silva, 2018; Santos et al, 2018).…”
Section: Physiological Outcomes Of Ace Inhibitionmentioning
confidence: 99%